We are live on
!
Find out more
PCML
Pavaki Capital Management LLC Portfolio holdings
AUM
$287M
This Fund
S&P 500
This Quarter
Est. Return
+12.26%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$255M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow
% of AUM
95.8%
Top 10 Holdings %
Top 10 Hldgs %
57.32%
Holding
131
New
131
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Milestone Pharmaceuticals
MIST
|
+$18.3M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$13.2M |
| 3 |
ARS Pharmaceuticals
SPRY
|
+$11.4M |
| 4 |
B
Barrick Mining
B
|
+$7.28M |
| 5 |
Walt Disney
DIS
|
+$6.72M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.54% |
| 2 | Materials | 10.85% |
| 3 | Communication Services | 4.97% |
| 4 | Technology | 3.95% |
| 5 | Industrials | 1.56% |
Similar funds
GCM
AWM
EA
MAG
PAM
MM
FCG
A
Pavaki Capital Management LLC's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Pavaki Capital Management LLC, which disclosed 131 positions worth $255M. Its ten largest holdings account for 57% of the portfolio.
Its largest position is Milestone Pharmaceuticals: 8,498,915 shares worth $17.2M.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, followed by Materials and Communication Services.
- Pavaki Capital Management LLC's largest Q4 2025 buy was Milestone Pharmaceuticals: 8,498,915 shares worth $17.2M.
- Pavaki Capital Management LLC's ten largest holdings make up 57% of its $255M portfolio in Q4 2025.
- Pavaki Capital Management LLC disclosed 131 positions in Q4 2025, its first 13F filing on record.
Based on Pavaki Capital Management LLC's 13F filing for Q4 2025, filed 7 Aug 2026.